Targeting the Receptor Tyrosine Kinase ROR1 by Small Molecules
- 7 September 2021
- book chapter
- Published by Springer Nature
- Vol. 269, 75-99
Abstract
Receptor tyrosine kinases (RTKs) are frequently dysregulated in malignancies and important for the malignant characteristics of tumor cells. RTKs are attractive structures for drug targeting of cancer. The RTK ROR1 is of significance during embryogenesis but downregulated in post-partum tissues. However, ROR1 is overexpressed in several hematological and solid tumors and important for tumor cell proliferation, survival, migration, and metastasis. WNT5a is a main ligand for ROR1. Several clinical trials are ongoing using anti-ROR1 antibody based drugs directed against the external domain (monoclonal antibodies, BiTE, CAR-T). We have produced small molecules (KAN834/1571c) fitting to the ATP pocket of the intracellular tyrosine kinase (TK) domain of ROR1 (TK inhibitor, TKI). These inhibitors of ROR1 prevented ROR1 phosphorylation and inactivated the WNT/β-catenin independent as well as WNT/β-catenin dependent pathways. ROR1-TKI induced apoptosis of ROR1 positive fresh patient derived tumor cells and appropriate cell lines and a dose and time dependent tumor reduction in animal models. In combination with other clinically relevant targeting drugs as venetoclax a synergistic apoptotic effect was seen. Two other small molecules (ARI-1 and strictinin) bound also to ROR1 and inhibited tumor growth. Development of small molecule ROR1 inhibitors is warranted to include this novel therapeutic approach for cancer therapy.Keywords
This publication has 99 references indexed in Scilit:
- Inhibition of the Receptor Tyrosine Kinase ROR1 by Anti-ROR1 Monoclonal Antibodies and siRNA Induced Apoptosis of Melanoma CellsPLOS ONE, 2013
- The Onco-Embryonic Antigen ROR1 Is Expressed by a Variety of Human CancersThe American Journal of Pathology, 2012
- The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapyBlood, 2011
- A Tissue-Specific Atlas of Mouse Protein Phosphorylation and ExpressionCell, 2010
- The B-cell tumor–associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptorBlood, 2010
- Nuclear localization of orphan receptor protein kinase (Ror1) is mediated through the juxtamembrane domainBMC Cell Biology, 2010
- STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cellsBlood, 2010
- Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5aProceedings of the National Academy of Sciences, 2008
- Receptor tyrosine kinases: mechanisms of activation and signalingCurrent Opinion in Cell Biology, 2007
- The discovery of receptor tyrosine kinases: targets for cancer therapyNature Reviews Cancer, 2004